Best of Hematology and Breast Cancer 2025, Phoenix

Scottsdale, AZ US
January 10, 2025 to January 11, 2025

The Best of Hematology and Breast Cancer 2025, Phoenix conference in Scottsdale, AZ is a CME-accredited, in-person event providing healthcare professionals with the latest updates in managing hematology and breast cancer. Drawing insights from the 66th ASH Annual Meeting (ASH24) and the San Antonio Breast Cancer Symposium (SABCS24), the conference features expert presentations on recent research and its clinical implications.

Focusing on a multidisciplinary approach, the event aims to integrate new advancements into patient-centered care. Designed for physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other professionals, attendees will engage with colleagues and experts to critically evaluate data and improve patient outcomes.

The Best of Hematology and Breast Cancer 2025, Phoenix, is an educational activity planned by the Binaytara Foundation. Neither Binaytara Foundation nor this activity are affiliated with the American Society of Hematology (ASH) or the San Antonio Breast Cancer Symposium (SABCS).

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee

Conference Director:

Binay Shah, MD, MHA Binaytara Foundation

Conference Co-Chairs:

Saurabh Chhabra, MD, MS - Mayo Clinic

Christine Saraceni, DO, MS - Ironwood Cancer & Research Centers

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Summarize the latest updates from ASH24 and SABCS24, focusing on their implications for clinical practice in managing hematologic disorders and breast cancer.
  2. Assess new therapeutic options for benign and malignant hematologic disorders and breast cancer, including appropriate indications and contraindications presented at ASH24 and SABCS24.
  3. Examine the study design, primary endpoints, and impact of recent and ongoing clinical trials from ASH24 and SABCS24 that have influenced current standards of care.
  4. Incorporate evolving diagnostic, prognostic, and therapeutic strategies from ASH24 and SABCS24 into patient management for hematologic disorders and breast cancer.
  5. Apply emerging data from clinical trials and updated expert guidelines from ASH24 and SABCS24 to individualize patient management strategies.

Hotel Room Reservation

A limited number of guestrooms are reserved at the Hilton Scottsdale Resort & Villas for the participants of this meeting at a discounted rate of $269 per night. The room rate doesn't include the resort fee of $30 per room per night or any applicable taxes.

CUTOFF - Thursday, January 9, 2025

Parking

Self-parking is covered in the resort fee. 

 

Course summary
Available credit: 
  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.
Course opens: 
08/05/2024
Course expires: 
04/10/2025
Event starts: 
01/10/2025 - 8:00am PST
Event ends: 
01/11/2025 - 12:30pm PST
Cost:
$250.00

DAY 1 – Friday, January 10, 2025

All times are listed in Pacific Standard Time (PST)

02:00 PM – 03:00 PM  Registration, Networking, & Exhibits


03:00 PM – 04:00 PM  Session 1: Case-Based Discussion: Classical Hematology

Session Chair: Mark Faber, DO

03:00 PM – 03:20 PM  Anemia - Soyoung “Sara” Park, MD

03:20 PM – 03:40 PM  Bone Marrow Failure + PNH - Yael Kusne, MD, PhD

03:40 PM – 04:00 PM  HUS/TTP - Zoey I. Harris, MD


04:00 PM – 05:00 PM  Session 2: Case-Based Discussion: Bleeding and Clotting Disorder

Session Chair: Surbhi Shah, MBBS

04:00 PM – 04:30 PM  Bleeding Disorders - Danielle Nance, MD

04:30 PM – 05:00 PM  Clotting Disorders - Akshay Amaraneni, MD


05:00 PM – 06:00 PM  Reception, Networking, & Exhibits 

 

DAY 2 – Saturday, January 11, 2025

07:00 AM – 08:00 AM  Registration, Exhibits, & Breakfast


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:30 AM – 09:30 AM  Session 3: Acute Leukemia

Session Chairs: Tibor Kovacsovics, MD

08:30 AM – 09:00 AM  Acute Myeloid Leukemia/MDS - Nathan Punwani, MD

09:00 AM – 09:30 AM  Acute Lymphoblastic Leukemia - Cecilia Y. Arana Yi, MD


09:30 AM – 10:45 AM  Session 4: Lymphoma

Session Chair: Javier L. Munoz, MD, MBA

09:30 AM – 09:55 AM  B-Cell Lymphoma - Rajesh Bagai, MD

09:55 AM – 10:20 AM  CLL - Abhijeet Kumar, MD

10:20 AM – 10:45 AM  T-Cell Lymphoma - Talal Hilal, MD


10:45 AM – 11:00 AM  Break & Exhibits


11:00 AM – 12:00 PM  Session 5: Multiple Myeloma

Session Chair: Erin E. Wiedmeier-Nutor, MD, MPH

11:00 AM – 11:30 AM  Frontline Therapy of Multiple Myeloma - Jeremy T. Larsen, MD

11:30 AM – 12:00 PM  Relapsed/Recurrent Multiple Myeloma - Sumit Madan, MD


12:00 PM – 01:00 PM  Lunch & Exhibits


01:00 PM – 02:00 PM Session 6: Hematologic Malignancies

Session Chair: Ambuga Badari, MD

01:00 PM – 01:30 PM  Myeloproliferative Neoplasms - Jeanne M. Palmer, MD

01:30 PM – 02:00 PM  Cellular Therapy - Sharad Khurana, MD


02:00 PM – 02:15 PM  Break & Exhibits


02:15 PM – 03:45 PM  Session 7: Updates in Management of Breast Cancer

Session Chair: Christine Saraceni, DO, MS

02:15 PM – 02:45 PM  HER2 Positive Breast Cancer - Victor Chiu, MD

02:45 PM – 03:15 PM  Triple Negative and HER2 Low Breast Cancer - Sima Ehsani, MD

03:15 PM – 03:45 PM  ER/PR Positive Breast Cancer - Hung T. Khong, MD


03:45 PM – 4:30 PM  Session 8: Tumor Board Style Case-Based Discussion: Breast Cancer

Session Chair: Christine Saraceni, DO, MS

03:45 PM – 03:55 PM  Inflammatory Breast cancer - Anu Batra, MD

03:55 PM – 04:05 PM  High Risk DCIS - Sonia Sandhu, MD

04:05 PM – 04:30 PM  Panel Discussion - Victor Chiu, MD; Sima Ehsani, MD; Anu Batra, MD; Sonia Sandhu, MD


04:30 PM  Adjourn

 

Hilton Scottsdale Resort & Villas
6333 North Scottsdale Road
Scottsdale, AZ 85250
United States

Hotel Room Reservation

A limited number of guestrooms are reserved at the Hilton Scottsdale Resort & Villas for the participants of this meeting at a discounted rate of $269 per night. The room rate doesn't include the resort fee of $30 per room per night or any applicable taxes.

CUTOFF - Thursday, January 9, 2025

Parking

Self-parking is covered in the resort fee.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Conference Chair(s)

Saurabh Chhabra

has a financial relationship (Grant Or Contract) with C4 Therapeutics;.
has a financial relationship (Other) with Ascentage Pharma;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Grant Or Contract) with CARSgen;.
has a financial relationship (Grant Or Contract) with Johnson & Johnson;.
has a financial relationship (Other) with Janssen;.
Session Chair(s)

Tibor Kovacsovics, MD

has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Gilead;.

Javier Munoz, MD MS MBA

has a financial relationship (Professional Services) with Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte;.
has a financial relationship (Other) with Targeted Oncology, OncView, Curio, and Physicians' Education Resource;.
has a financial relationship (Financial Support) with Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene;.
has a financial relationship (Professional Services) with MEI, TG Therapeutics, AstraZeneca, Eli Lilly;.
Speaker/Topic Presenter(s)

Cecilia Arana Yi

has no relevant financial relationships to disclose at this time.

Victor Chiu

has a financial relationship (Stock) with Revolution Medicine;.

Sima Ehsani, MD

has no relevant financial relationships to disclose at this time.

Zoey Harris

has no relevant financial relationships to disclose at this time.

Hung Khong, MD

has a financial relationship (Stock) with TG Therapeutics;.
has a financial relationship (Stock) with Agenus;.
has a financial relationship (Stock) with MiNK Therapeutics;.

Sharad Khurana, MD, MSc

has no relevant financial relationships to disclose at this time.

Sumit Madan

has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Karyopharm;.

Julia Wiedmeier-Nutor, MD. MPH

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported with Independent Medical Education grants from:

  • Exact Sciences
  • Incyte

Available Credit

  • 8.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$250.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.